Comparative Pharmacology
Head-to-head clinical analysis: FANAPT versus RISPERDAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FANAPT versus RISPERDAL.
FANAPT vs RISPERDAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FANAPT (iloperidone) is an atypical antipsychotic that exhibits high affinity for serotonin 5-HT2A and dopamine D2 receptors, with additional antagonism at alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors. The therapeutic efficacy is primarily attributed to combined 5-HT2A and D2 receptor antagonism.
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
12-24 mg orally once daily, titrated from 1 mg twice daily on day 1, 2 mg twice daily on day 2, 4 mg twice daily on day 3, 6 mg twice daily on day 4, 8 mg twice daily on day 5, then 10 mg twice daily on day 6 and 7, followed by 12 mg once daily on day 8. Maximum dose: 24 mg/day.
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 22-30 hours) for the sum of parent drug and active metabolites (P95, P88, and P86); steady-state achieved within 4-5 days.
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
Renal (approximately 80% as metabolites, <1% as parent drug) and fecal (approximately 20% as metabolites).
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic